To the Editor:
The signal transducer and activator of transcription 5B (STAT5B), downstream of IL-15 signaling and Janus kinase (JAK)1, and 3-mediated activation, is a master regulator of development, survival, and function of innate and innatelike lymphocytes (including natural killer (NK) and NKT cells) [1] [2] [3] . Gain-of-function mutations in the SH2 domain of human STAT5B, especially STAT5B
N642H
, are associated with aggressive forms of CD56 + T cell (NKT) and NK cell lymphomas/leukemias [4] [5] [6] . We described a mouse model expressing human (h)STAT5B N642H under the Vav-1 promoter, which develops severe CD8 + T cell neoplasia [7] .
Here, we explore the ability of hSTAT5B N642H to serve as an oncogenic driver in innate lymphocyte neoplasms.
We found an increase in absolute NK cell numbers in the spleen of T cell-diseased hSTAT5B N642H transgenic compared to wild-type (WT) mice (Fig. 1a) , despite the relative decrease of the proportion of NK cells among splenic lymphocytes (Fig. S1A) , while nonmutant hSTAT5B control mice showed intermediate NK cell numbers (Fig. 1a,   Fig. S1A ). No significant differences in NK cell numbers were observed in the bone marrow (BM) between genotypes (Fig. S1B ). In addition, both hSTAT5B and hSTAT5B N642H mice showed a similar increase in the proportion of mature NK cells (CD27
−

CD11b
+ and KLRG1 + ) in the spleen (Fig. S1C, D) . These findings suggest that the enforced expression of nonmutant hSTAT5B is sufficient to boost NK cell maturation, which is not further enhanced by introducing the activating hSTAT5B mutation. We hypothesized that any phenotypic alterations affecting innate lymphocytes might be masked by the hSTAT5B N642H -driven aggressive CD8 + T cell disease established in hSTAT5B N642H mice at the age of 6-8 weeks [7] . To explore the potential of hSTAT5B N642H to promote NK cell expansion in vivo, we transplanted CD3-depleted BM from hSTAT5B N642H or hSTAT5B mice in immune-deficient Rag2 −/− γc −/− recipient mice. Using this approach, we observed an enhanced expansion of NK cells in the blood of hSTAT5B N642H compared to hSTAT5B-transplanted recipients over a time course of 4 weeks (Fig. 1b) . Long-term analysis of NK cells in hSTAT5B N642H -transplanted mice was not possible due to expansion of residual CD8 + T cells (Fig. S1E, F) , which forced us to terminate the experiment. However, after 4 weeks, increased numbers of NK cells were also detected in the spleen upon transplantation of CD3-depleted hSTAT5B N642H compared to hSTAT5B BM (Fig. S1G) .
To investigate long-term effects of hSTAT5B N642H on innate lymphocytes, we sorted Lineage (Lin) compared to hSTAT5B BM cells was observed (Fig. S1H) , whereas we failed to detect CD8 + T cells in the blood of the recipient animals (Fig. S1I ). This indicated that our sorting strategy successfully eliminated CD8 + T cell disease, but did not allow us to uncover persistent hSTAT5B
N642H
-mediated NK cell expansion. Of note, after 4.5-10 months all three hSTAT5B Table S1 ). Disease development was restricted to transplantation of mutant hSTAT5B cells and was not detected upon transplantation of hSTAT5B BM, despite following up these animals for 10 months.
To investigate, whether hSTAT5B N642H NKT cells are indeed transformed and fulfill the criteria of being leukemic, we started to perform serial whole BM transplants from the earlier diseased recipient #1 (survival: 133 d) with the presumably more aggressive disease. To do so, we transplanted BM containing 1 × 10 6 NKT cells into immune-deficient Rag2
This serial transplantation approach was continued for a total of six rounds. The first two rounds were performed to maintain and amplify the NKT cell disease. We confirmed the presence of the hSTAT5B N642H transgene in a diseased mouse (Fig. S1J ). Upon the 3rd to the 6th round of serial transplant, we characterized the manifested disease as an aggressive leukemia accompanied by hepatosplenomegaly ( Fig. 2a) , increased white blood cell (WBC) counts ( Fig. S2A ) and a high frequency of NKT cells in blood, BM, spleen, and liver ( Fig. S2C, D) with a mean survival of 17.6 days (Fig. S2B) . Infiltration of leukemic cells into various organs was confirmed by histological analysis (Fig. S2E ). In the 6th round, a titration of transplanted NKT cell numbers was performed. Disease severity at the end point was comparable, while a delay of 3 days occurred between each titration step (Fig. 2a, Fig. S2A-D) . Despite the increased disease latency in recipients #2 (survival: 294 d) and #3 (survival: 301 d), the disease could also be serially transplanted giving rise to a similarly aggressive disease ( Fig. S3A-H) as for recipient #1.
A more detailed characterization of surface markers on transformed NKT cells from the serially transplanted disease of recipient #1 verified expression of the T cell receptor (TCR) β chain, while CD4, CD8, and TCRγδ expression was not detected. Leukemic cells also stained positive for CD122 and the NK cell markers NKp46 and DX5. No interaction with the CD1d tetramer was observed (Fig. 2b) . This surface marker profile corresponds to previously described CD1d-independent NKT cells [8, 9] , which were recently identified as a source for CD3
leukemia in IL-15 transgenic mice [10] . In analogy to our NKT cell leukemia model, human CD56 + T-LGL leukemia cells were also shown to express NKp46 [10] . Additionally, CD3
+ CD56 + blasts in human T-LGL leukemia express CD8 [4] . Interestingly, we found CD8 expressed on a subset of hSTAT5B N642H NKT leukemia cells in the two later diseased recipients #2 and #3, but not in recipient #1 (Table S1) .
Furthermore, the serially transplanted leukemic NKT cells from recipient #1 were largely negative for activating and inhibitory NK cell receptors, except for Ly49G2 and KLRG1 (Fig. S4A) , but stained positive for CD43, CD44, and CD69, while lacking CD62L (Fig. S4A) . In summary, this surface receptor expression profile is consistent with an activated phenotype comparable to the leukemic blasts found in IL-15 transgenic mice [11] . The fact that IL-15 transgenic mice develop NK1.1 + T-LGL (NKT) or NK cell leukemia [10, 11] supports the importance of the IL- -driven CD8 + T cell disease is susceptible to JAK1/JAK2 inhibition by Ruxolitinib treatment [7] . As JAK inhibitors have also been suggested as therapeutic strategy for NK/T-cell lymphoma and aggressive NK cell leukemia [6, 12] , we transplanted NSG mice with hSTAT5B N642H NKT leukemia cells and treated them with ruxolitinib for 3 weeks. Treatment attenuated disease severity and decreased hepatosplenomegaly and WBC counts compared to the control group (Fig. 2c and Fig. S4B ).
Although initial attempts to grow transformed NKT cells in vitro failed, after 6-8 weeks we detected outgrowth of hSTAT5B N642H NKT cell lines from cultured hepatic leukocytes of three out of nine NSG mice from different serial transplant rounds from recipient #1 (Table S2 , Fig. S5A ). Two cell lines, derived from the same mouse cultured without or with IL-2 (4165_1 and 4165_2, respectively), were treated with Ruxolitinib and remained sensitivity towards it (IC 50 of 83 and 72.5 nM, respectively) (Fig. S5B) . Furthermore, these cell lines could give rise to leukemia when injected into immune-competent Ly5.1/ CD45.1 + mice (Fig. S5C-E) .
In this study, we identify STAT5B N642H as an oncogenic driver in innate-like lymphocytes. Our novel NKT leukemia 
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